

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/206339 A1

(51) International Patent Classification:

C07D 217/16 (2006.01) C07D 417/12 (2006.01)
C07D 401/12 (2006.01) C07D 471/04 (2006.01)
C07D 405/12 (2006.01) C07D 471/08 (2006.01)
C07D 405/14 (2006.01) C07D 519/00 (2006.01)
C07D 409/12 (2006.01) A61P 9/00 (2006.01)
C07D 413/12 (2006.01) A61K 31/395 (2006.01)

(21) International Application Number:

PCT/US2024/021528

(22) International Filing Date:

26 March 2024 (26.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/492,441 27 March 2023 (27.03.2023) US

(71) Applicant: **EDGEWISE THERAPEUTICS, INC.**
[US/US]; 1715 38th Street, Boulder, Colorado 80301 (US).

(72) Inventors: **HAWRYLUK, Natalie Anne**; 1715 38th Street, Boulder, Colorado 80301 (US). **SCHLACHTER, Stephen Thomas**; 1715 38th Street, Boulder, Colorado 80301 (US). **KOCH, Kevin**; 1715 38th Street, Boulder, Colorado 80301 (US). **LUZZIO, Michael Joseph**; 1715 38th Street, Boulder, Colorado 80301 (US). **RUSSELL, Alan James**; 1715 38th Street, Boulder, Colorado 80301 (US). **EVANCHIK, Marc Justin**; 1715 38th Street, Boul-

der, Colorado 80301 (US). **DEL RIO, Carlos Luis**; 1715 38th Street, Boulder, Colorado 80301 (US).

(74) Agent: **MARGULIEUX, Grant**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))


(54) Title: QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF




(I)



(II-A)



(III)



(IV)

(57) Abstract: The present disclosure generally relates to substituted quinolinone amide compounds or salts of Formula (I), (II-A), (IV), or (III) and pharmaceutical compositions thereof. The substituted quinolinone amide compounds or salts of Formula (I), (II-A), (IV), or (III) disclosed herein may be used to treat or prevent cardiac disease in an individual in need thereof.

[Continued on next page]

WO 2024/206339 A1

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*